Biofrontera Inc.’s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards
WOBURN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company…
News
AmMax Bio Provides Update on AMB-05X Program for Tenosynovial Giant Cell Tumor (TGCT)
New Patents Issued and Fast Track Designation Support Development of the Only Locally-Administered Drug Treatment…
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
– Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target…
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis
MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with…
Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America
WARRINGTON, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology…
TFF Pharmaceuticals to Participate in the Roth Inaugural Healthcare Opportunities Conference
FORT WORTH, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage…
Enzo Biochem, Inc. Launches AMPIVIEW™ Gene Expression Platform with First Products Targeting Detection of HPV and SARS-CoV-2
Powered by Enzo’s LoopRNA™ ISH technology, a new platform designed for superior sensitivity in detection…
eFFECTOR Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer
SAN DIEGO and REDWOOD CITY, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics, Inc….
Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis
Study met both co-primary endpoints and all secondary endpoints At week eight, 67.3% of individuals…
Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (Celularity), a…
Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology…
Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer
BURNABY, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) — Qu Biologics Inc., a clinical stage…
Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy
Results highlight a potential novel treatment for diabetic and other retinopathies Unique Wnt-mediated mechanism increases…
Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting
The first two Fanconi Anemia patients receiving JSP191 achieved 100% donor chimerism JSP191 safe to…
Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a…
Secure Transfusion Solutions Announces it will Present New Data and Participate at the 2022 AABB Annual Meeting
AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) — Secure Transfusion Solutions (STS), a private life…
Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022
SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision…
Immutep to Participate in Two Upcoming Investor Conferences
SYDNEY, AUSTRALIA, Sept. 26, 2022 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”…
Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor
~ Under the Terms of the Previously Announced Investment Agreement, $5 Million Already Funded Upon…
Theratechnologies to Announce Third Quarter 2022 Financial Results and Provide Business Update
MONTREAL, Sept. 26, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a…